ANL 31.82 Increased By ▲ 0.27 (0.86%)
ASC 20.99 Increased By ▲ 0.19 (0.91%)
ASL 23.85 Decreased By ▼ -0.15 (-0.63%)
BOP 8.25 Increased By ▲ 0.08 (0.98%)
BYCO 10.19 Decreased By ▼ -0.05 (-0.49%)
FCCL 22.65 Increased By ▲ 0.05 (0.22%)
FFBL 27.75 Increased By ▲ 0.55 (2.02%)
FFL 21.32 Increased By ▲ 0.12 (0.57%)
FNEL 9.15 Decreased By ▼ -0.03 (-0.33%)
GGGL 27.97 Decreased By ▼ -0.06 (-0.21%)
GGL 46.90 Increased By ▲ 0.15 (0.32%)
HUMNL 7.57 Increased By ▲ 0.02 (0.26%)
JSCL 23.00 Increased By ▲ 0.07 (0.31%)
KAPCO 39.90 Decreased By ▼ -0.20 (-0.5%)
KEL 3.97 Increased By ▲ 0.03 (0.76%)
MDTL 3.82 Increased By ▲ 0.01 (0.26%)
MLCF 45.40 Increased By ▲ 0.30 (0.67%)
NETSOL 168.70 Increased By ▲ 1.35 (0.81%)
PACE 8.02 Decreased By ▼ -0.01 (-0.12%)
PAEL 34.60 Decreased By ▼ -0.27 (-0.77%)
PIBTL 11.30 Decreased By ▼ -0.05 (-0.44%)
POWER 9.32 Decreased By ▼ -0.03 (-0.32%)
PRL 24.02 Decreased By ▼ -0.11 (-0.46%)
PTC 11.82 Increased By ▲ 0.07 (0.6%)
SILK 1.85 Increased By ▲ 0.02 (1.09%)
SNGP 50.80 Decreased By ▼ -0.38 (-0.74%)
TELE 15.55 Decreased By ▼ -0.02 (-0.13%)
TRG 168.71 Increased By ▲ 0.65 (0.39%)
UNITY 43.75 Decreased By ▼ -0.09 (-0.21%)
WTL 3.89 Increased By ▲ 0.07 (1.83%)
BR100 5,208 Increased By ▲ 31.56 (0.61%)
BR30 26,881 Increased By ▲ 170.15 (0.64%)
KSE100 47,892 Increased By ▲ 219.11 (0.46%)
KSE30 19,194 Increased By ▲ 86.8 (0.45%)

Coronavirus
VERY HIGH Source: covid.gov.pk
Pakistan Deaths
23,087
3924hr
Pakistan Cases
1,011,708
3,26224hr
6.6% positivity
Sindh
369,245
Punjab
353,695
Balochistan
29,681
Islamabad
85,947
KPK
142,139
World

Oxford University to test COVID-19 vaccine response among children for first time

  • The new mid-stage trial will determine whether the vaccine is effective on people between the ages of 6 and 17.
  • Around 300 volunteers will be enrolled and first inoculations are expected this month, Oxford said.
13 Feb 2021

The University of Oxford has launched a study to assess the safety and immune response of the COVID-19 vaccine it has developed with AstraZeneca Plc in children for the first time, it said on Saturday.

The new mid-stage trial will determine whether the vaccine is effective on people between the ages of 6 and 17, according to an emailed statement from the university.

Around 300 volunteers will be enrolled and first inoculations are expected this month, Oxford said.

The two-dose Oxford/AstraZeneca vaccine has been hailed as a 'vaccine for the world' because it is cheaper and easier to distribute than some rivals.

AstraZeneca has a target to produce 3 billion doses this year and aims to produce over 200 million doses per month by April.